These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 29779485)

  • 1. TGN-1412 and BIA-2474 Trials with Tragic End: Lessons Learnt To Make Clinical Trials Safer.
    Kaur RJ; Singh S; Sidhu P; Sharma PK
    Rev Recent Clin Trials; 2018; 13(4):252-256. PubMed ID: 29779485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of the BIA-102474-101 study for review of first-into-human clinical trials.
    Eddleston M; Cohen AF; Webb DJ
    Br J Clin Pharmacol; 2016 Apr; 81(4):582-6. PubMed ID: 26996741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons from the fatal French study BIA-10-2474.
    Moore N
    BMJ; 2016 May; 353():i2727. PubMed ID: 27193592
    [No Abstract]   [Full Text] [Related]  

  • 4. First-in-human dose: current status review for better future perspectives.
    Mishra A; Sarangi SC; Reeta K
    Eur J Clin Pharmacol; 2020 Sep; 76(9):1237-1243. PubMed ID: 32488334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of phase I clinical trials with monoclonal antibodies in Germany--the regulatory requirements viewed in the aftermath of the TGN1412 disaster.
    Liedert B; Bassus S; Schneider CK; Kalinke U; Löwer J
    Int J Clin Pharmacol Ther; 2007 Jan; 45(1):1-9. PubMed ID: 17256444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase.
    Kerbrat A; Ferré JC; Fillatre P; Ronzière T; Vannier S; Carsin-Nicol B; Lavoué S; Vérin M; Gauvrit JY; Le Tulzo Y; Edan G
    N Engl J Med; 2016 Nov; 375(18):1717-1725. PubMed ID: 27806235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open letter on access to the BIA 10-2474 clinical trial data.
    Brøsen K; Funck-Brentano C; Kroemer HK; Pirmohamed M; Schwab M
    Lancet; 2017 Jan; 389(10065):156. PubMed ID: 27955829
    [No Abstract]   [Full Text] [Related]  

  • 8. Statistical issues in first-in-human studies on BIA 10-2474: Neglected comparison of protocol against practice.
    Bird SM; Bailey RA; Grieve AP; Senn S
    Pharm Stat; 2017 Mar; 16(2):100-106. PubMed ID: 28206702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A call to incorporate systems theory and human factors into the existing investigation of harm in clinical research involving healthcare products.
    Edwards BD; Bégaud B; Daemen E; Dokas I; Fishbein JM; Greenberg HE; Hochberg A; Le Louet H; Lyngvig J; Mogles N; Owen K; Prendergast C; Rejzek M; Trantza S; Webb DJ; Whalen M; Whiteley S
    Br J Clin Pharmacol; 2017 Nov; 83(11):2339-2342. PubMed ID: 28681444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Not Available].
    Funck-Brentano C; Ménard J
    Presse Med; 2016 Sep; 45(9):719-22. PubMed ID: 27666586
    [No Abstract]   [Full Text] [Related]  

  • 11. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe?
    Tranter E; Peters G; Boyce M; Warrington S
    Br J Clin Pharmacol; 2013 Aug; 76(2):164-72. PubMed ID: 23438102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of biologics, lessons learnt from TGN1412.
    Stebbings R; Poole S; Thorpe R
    Curr Opin Biotechnol; 2009 Dec; 20(6):673-7. PubMed ID: 19892543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474.
    van Esbroeck ACM; Janssen APA; Cognetta AB; Ogasawara D; Shpak G; van der Kroeg M; Kantae V; Baggelaar MP; de Vrij FMS; Deng H; Allarà M; Fezza F; Lin Z; van der Wel T; Soethoudt M; Mock ED; den Dulk H; Baak IL; Florea BI; Hendriks G; De Petrocellis L; Overkleeft HS; Hankemeier T; De Zeeuw CI; Di Marzo V; Maccarrone M; Cravatt BF; Kushner SA; van der Stelt M
    Science; 2017 Jun; 356(6342):1084-1087. PubMed ID: 28596366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Commentary: Fatal French Clinical Trial: What Can We Learn from What Went Wrong?
    Skaper SD
    CNS Neurol Disord Drug Targets; 2016; 15(7):752-3. PubMed ID: 27549166
    [No Abstract]   [Full Text] [Related]  

  • 17. Take Care of the Fast-in-Human Study.
    van Hoogdalem EJ
    Clin Transl Sci; 2017 May; 10(3):122-123. PubMed ID: 27981812
    [No Abstract]   [Full Text] [Related]  

  • 18. Computational proteome-wide screening predicts neurotoxic drug-protein interactome for the investigational analgesic BIA 10-2474.
    Molinski SV; Shahani VM; MacKinnon SS; Morayniss LD; Laforet M; Woollard G; Kurji N; Sanchez CG; Wodak SJ; Windemuth A
    Biochem Biophys Res Commun; 2017 Jan; 483(1):502-508. PubMed ID: 28007597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The storm has cleared: lessons from the CD28 superagonist TGN1412 trial.
    Hünig T
    Nat Rev Immunol; 2012 Apr; 12(5):317-8. PubMed ID: 22487653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-clinical toxicology evaluation of BIA 10-2474.
    Hayes AW; Weber K; Moser P; Soares-da-Silva P
    Crit Rev Toxicol; 2021 Jan; 51(1):65-75. PubMed ID: 33528291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.